[HTML][HTML] Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell …
M Reck, EB Garon, L Paz-Ares, S Ponce, JC Jaime… - Clinical lung cancer, 2018 - Elsevier
Background Despite the likelihood of an initial response to an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non–small-cell lung cancer …
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non–small-cell lung cancer …
RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated …
K Nakagawa, EB Garon, T Seto, M Nishio, S Ponce Aix… - 2019 - ascopubs.org
9000 Background: Dual blockade of EGFR and VEGFR pathways in EGFRm NSCLC
augments anti-tumor efficacy versus (v) EGFR inhibition alone. RELAY (NCT02411448) …
augments anti-tumor efficacy versus (v) EGFR inhibition alone. RELAY (NCT02411448) …
Activity of erlotinib when dosed below the maximum tolerated dose for EGFR‐mutant lung cancer: Implications for targeted therapy development
BL Lampson, M Nishino, SE Dahlberg, D Paul… - Cancer, 2016 - Wiley Online Library
BACKGROUND Erlotinib is a standard first‐line therapy for patients who have metastatic
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
Treatment rationale and study design for the RELAY study: a multicenter, randomized, double-blind study of erlotinib with ramucirumab or placebo in patients with …
EB Garon, M Reck, L Paz-Ares, S Ponce, JC Jaime… - Clinical Lung Cancer, 2017 - Elsevier
Introduction We present the treatment rationale and study design for the RELAY study
(NCT02411448). This phase Ib/III study will assess safety, tolerability, and efficacy of the …
(NCT02411448). This phase Ib/III study will assess safety, tolerability, and efficacy of the …
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled …
K Nakagawa, EB Garon, T Seto, M Nishio… - The Lancet …, 2019 - thelancet.com
Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …
Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell …
K Yoh, S Atagi, M Reck, EB Garon… - Current Medical …, 2020 - Taylor & Francis
Objective In the phase 3 RELAY trial, ramucirumab/erlotinib demonstrated superior
progression-free survival (PFS) over placebo/erlotinib in patients with EGFR-mutated …
progression-free survival (PFS) over placebo/erlotinib in patients with EGFR-mutated …
[HTML][HTML] RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe …
SP Aix, S Novello, EB Garon, K Nakagawa… - Cancer Treatment and …, 2021 - Elsevier
Background In EGFR mutation-positive NSCLC, dual EGFR/VEGFR inhibition compared to
EGFR alone increases anti-tumor efficacy. The Phase III RELAY trial demonstrated superior …
EGFR alone increases anti-tumor efficacy. The Phase III RELAY trial demonstrated superior …
The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer
M Boussageon, A Swalduz, M Pérol - Expert Review of Anticancer …, 2021 - Taylor & Francis
Introduction EGFR-tyrosine kinase inhibitors (TKIs) changed the natural history of EGFR-
mutant advanced NSCLC patients, but acquired resistance is inevitable. New strategies are …
mutant advanced NSCLC patients, but acquired resistance is inevitable. New strategies are …
Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non–small cell lung cancer: a phase 2 …
TE Stinchcombe, PA Jänne, X Wang, EM Bertino… - JAMA …, 2019 - jamanetwork.com
Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …
Erlotinib for metastatic non-small-cell lung cancer: first-, second-or third-line setting–does it matter? A single-institution experience
S Ailawadhi, L Derby, R Natarajan, G Fetterly, M Reid… - Oncology, 2009 - karger.com
Background: Erlotinib is approved as treatment for metastatic non-small-cell lung cancer
(NSCLC), following failure of initial therapy. Studies to define patients that derive maximal …
(NSCLC), following failure of initial therapy. Studies to define patients that derive maximal …